Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03016533 · ClinicalTrials.gov registry record · Phase 3
Dolutegravir Study in HIV-1 Participants Completing IMPAACT Studies P1093 and P2019
A Phase 3 study of HIV Infections, sponsored by ViiV Healthcare.
- Completed
- Registry status
- Phase 3
- Development phase
- 100
- Enrollment target
- 17
- Study locations
NCT03016533 is a Phase 3 study of HIV Infections that has completed, run by ViiV Healthcare. The registered enrollment target is 100 participants, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (78% lower). The trial reports 17 study locations across 4 states.
The verdict
NCT03016533, a Phase 3 study of HIV Infections, has completed, sponsored by ViiV Healthcare.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 100 participants
- Enrollment target
- 17
- Study locations
Study Summary
Dolutegravir is a potent integrase strand transfer inhibitor. Abacavir/dolutegravir/lamivudine (ABC/DTG/3TC) is a fixed dose combination regimen containing two nucleoside reverse transcriptase inhibitors and dolutegravir. This is a phase 3b, non-randomized, open-label, multi-center, two treatment rollover study. The primary objective of this pediatric interventional study is to provide continued access to age appropriate formulations of investigational product (dolutegravir), either as Tivicay or as part of fixed dose combination ABC/DTG/3TC, for eligible participants who previously participated in parent studies P1093 (NCT01302847) or P2019 (NCT03760458) and who cannot locally access age appropriate formulations of dolutegravir or ABC/DTG/3TC in the public sector. The P1093 study was designed to evaluate the pharmacokinetics (PK), safety, tolerability and antiviral activity of dolutegravir in combination with optimized background regimens in human immunodeficiency virus type 1 (HIV-1) experienced adolescents and children as well as treatment naïve infants and toddlers. The P2019 study was designed to evaluate PK, safety, tolerability and antiviral activity of ABC/DTG/3TC dispersible and immediate release tablets in HIV-1-infected children. Participants who have tolerated investigational product in the parent studies without any significant toxicity or signs of virologic failure leading to the permanent discontinuation of investigational product and withdrawal from the parent study will be considered for this open label continued access study. Participants will receive their age/weight appropriate dose of investigational product as defined in the parent study. The duration of participation in the study will extend until age appropriate formulations of Tivicay or ABC/DTG/3TC receive local (by country) regulatory approval and are available in those countries from another source (e.g. government programs, aid programs, assistance programs, etc.) or the participant is n
Conditions Studied
Interventions
- DRUG Dolutegravir film-coated tablets
- DRUG Dolutegravir film-coated dispersible tablets
- DRUG ABC/DTG/3TC immediate release tablets
- DRUG ABC/DTG/3TC film-coated dispersible tablets
Study Locations (17)
Other
- GSK Investigational Site - Gaborone
- GSK Investigational Site - Belo Horizonte
- GSK Investigational Site - Nova Iguaçu
- GSK Investigational Site - RibeirAo PretoSP
- GSK Investigational Site - Rio de Janeiro
- GSK Investigational Site - Cape Town
- GSK Investigational Site - Johannesburg
- GSK Investigational Site - Soweto
- GSK Investigational Site - Umlazi
- GSK Investigational Site - Moshi
- GSK Investigational Site - Bangkok
- GSK Investigational Site - Chiang Mai
- GSK Investigational Site - Chiang Rai
- GSK Investigational Site - Harare
California
- GSK Investigational Site - Los Angeles
Florida
- GSK Investigational Site - Fort Lauderdale
Tennessee
- GSK Investigational Site - Memphis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2017-06-06 |
| Est. Completion | 2024-12-24 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03016533
The ClinicalTrials.gov registry entry for NCT03016533 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (78% lower). The listed sponsor is ViiV Healthcare, which has 182 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with HIV Infections appearing as the primary indexed condition, and to 4 interventions - of which Dolutegravir film-coated tablets is the first listed.
NCT03016533 reports 17 study locations spanning 4 distinct geographic areas - top geographies include Other, California, Florida.
Frequently Asked Questions
What is clinical trial NCT03016533 about?
NCT03016533 is a clinical study titled "Dolutegravir Study in HIV-1 Participants Completing IMPAACT Studies P1093 and P2019". Dolutegravir is a potent integrase strand transfer inhibitor. Abacavir/dolutegravir/lamivudine (ABC/DTG/3TC) is a fixed dose combination regimen containing two nucleoside reverse transcriptase inhibitors and dolutegravir. This is a phase 3b, non-randomized, open-label, multi-center, two treatment ro...
What is the current status of trial NCT03016533?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 100 participants. The study started on 2017-06-06. Estimated completion is 2024-12-24.
What conditions does trial NCT03016533 study?
This clinical trial studies the following conditions: HIV Infections.
What interventions are being tested in trial NCT03016533?
The interventions under investigation include: Dolutegravir film-coated tablets (DRUG), Dolutegravir film-coated dispersible tablets (DRUG), ABC/DTG/3TC immediate release tablets (DRUG), ABC/DTG/3TC film-coated dispersible tablets (DRUG).
Who is sponsoring clinical trial NCT03016533?
This trial is sponsored by ViiV Healthcare, which has 182 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03016533 being conducted?
This trial has 17 study locations across California, Florida, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV Infections
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate the Effectiveness of Long-acting (LA) Cabotegravir (CAB) + Rilpivirine (RPV) LA When Given to Participants With Detectable HIV-1
RECRUITING · Phase 3
-
Testing a Real-time Electronic Antiretroviral Adherence Monitoring Intervention
RECRUITING · Phase 3
-
SmartSteps: A Context-Aware, PrEP Adherence Intervention for Individuals With Substance Use Disorder
RECRUITING · Phase 3
-
Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine From Current Antiretroviral Regimen in Virologically Suppressed HIV-1-infected Adults
ACTIVE NOT RECRUITING · Phase 3
-
A Study to Evaluate Efficacy, Safety and Tolerability in Antiretroviral Therapy (ART)-Experienced Participants of at Least 50 Years of Age Living With Human Immunodeficiency Virus (HIV) With Virologic Suppression Who Switch to DTG/3TC FDC From BIC/FTC/TAF
ACTIVE NOT RECRUITING · Phase 3
-
The LATITUDE Study: Long-Acting Therapy to Improve Treatment SUccess in Daily LifE
ACTIVE NOT RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.